Skip to main content
. 2016 Mar 4;23(5):733–747. doi: 10.1038/cdd.2015.174

Table 2. Main formulations of TRAIL fusion proteins.

Fusion protein Target Main effects Experimental testing Ref.
MBOS4:TRAIL FAP Increased bioactivity Active targeting Fibrosarcoma cell lines in vitro 69
         
CD40ed:TRAILed CD40 Increased bioactivity Active targeting Fibrosarcoma cell lines in vitro 214
         
scFv425:sTRAIL EGFR Increased drug bioavailability Active targeting Absence of side effects Pharmacokinetic studies in vivo Tumor xenograft model (RCC) in vivo 189
    Increased antitumor activity Hematologic and solid tumor cell lines in vitro 190
         
scFvCD19:sTRAIL CD19 Active targeting Absence of side effects Increased antitumor activity Hematologic tumor cell lines and B-CLL primary cells in vitro Tumor xenograft model (B-ALL) in vivo 185
         
scFvCD33:sTRAIL CD33 Active targeting Increased antitumor activity Hematologic tumor cell lines and AML primary cells in vitro 186
         
Anti-MCSP:TRAIL MCSP Active targeting Absence of side effects Increased antitumor activity Melanoma cell lines and normal primary cells in vitro Tumor xenograft model (melanoma) in vivo 188
         
DbaEGFR-scTRAIL EGFR Active targeting Absence of side effects Increased antitumor activity HCC and CRC cell lines in vitro Tumor xenograft model (CRC) in vivo 145
         
Anti-CD3:TRAIL K12:TRAIL CD3 CD7 Enhanced T-cell activity Increased antitumor activity Hematologic, solid tumor cell lines and tumor primary cells in vitro Tumor xenograft model (CRC) in vivo 196
         
scFvCD70:TRAILmutRs CD70 Increased bioactivity Active targeting Hematologic and solid tumor cell lines in vitro 70
         
scFv:G28-TRAIL CD40 Increased bioactivity Active targeting Induction of DC maturation Fibrosarcoma cell lines in vitro 195
         
MSC.scFvCD20-sTRAIL CD20 Active targeting Absence of side effects Increased antitumor activity Hematologic tumor cell lines and normal primary cells in vitro Tumor xenograft model (NHL) in vivo 187
         
CLL1:TRAIL CLL1 Enhanced T-cell activity Increased antitumor activity Absence of side effects Hematologic and solid tumor cell lines in vitro 202
         
RGD:TRAIL Integrins Active targeting Increased antitumor activity BC and CRC cell lines in vitro Tumor xenograft model (NHL) in vivo 203
         
scTRAIL: Fc (APG350) — Increased antitumor activity Several cell lines in vitro Tumor xenograft model (CRC) in vivo 209
         
scFv-EHD2-scTRAIL — Increased antitumor activity Active targeting Several cell lines in vitro Tumor xenograft model (CRC) in vivo 211
         
FN14:TRAIL TWEAK Increased antitumor activity Absence of side effects HCC cell lines in vitro Tumor xenograft model (HCC) in vivo 192
    Increased anti-inflammatory effect Multiple sclerosis experimental model in vivo 193

Abbreviations: AML, acute myeloid leukemia; B-ALL, B-cell acute lymphoblastic leukemia; BC, breast cancer; B-CLL, B-cell chronic lymphocytic leukemia; CRC, colorectal carcinoma; DC, dendritic cell; EGFR, epidermal growth factor receptor; HCC, hepatocellular carcinoma; MCSP, melanoma-associated chondroitin sulfate proteoglycan; MSC, mesenchymal stem cells; NHL, non-Hodgkin's lymphoma; RCC, renal cell carcinoma; RGD, peptide with the sequence ACDCRGDCFC; scFv, single-chain variable region.